These data show that in a panel of BRAF-mutant advanced thyroid cancer cell lines sensitive or resistant to MEKi, most, but not all, exhibit moderate to strong synergistic inhibition of cell viability in response to combined BRAF/MEK1/2 inhibition. This evidence concerns the gene BRAF and thyroid gland carcinoma.